Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)–negative breast cancer have poor prognoses. The benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback